3 completed. 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 1 | Completed 1 |
Follow Prevenar13®: new trials by email Literature Review of Prevenar13® trials Research Report on Prevenar13®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of PCV24 in Children Aged 2-17 Years Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Prevenar13® - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Life Sciences Co., Ltd. | 119 | 2024-09-07 | 2026-01-28 |
| Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years PCV24 formulation 1, PCV24 formulation 2, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Pneumococcal Infectious Disease | Phase 1 | Completed | Reinovax Biologics Co., LTD | 230 | 2024-04-27 | 2026-08-17 |
| Protection Against Pneumococcal Infection in Children With T1DM 13-valent pneumococcal conjugate vaccine (PCV13) - Type 1 Diabetes Mellitus | Phase 4 | Completed | University of Oxford | 50 | 2013-08-01 | 2017-05-09 |
Pneumococcal Infections (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1)
Reinovax Biologics Co., LTD (1) · Sinovac Life Sciences Co., Ltd. (1) · University of Oxford (1)
China (2) · United Kingdom (1)
Kai Chu (1) · Yunong Zhang, Master (1)